Wedbush maintains Beam Therapeutics at Outperform, raises price target to $30 from $28

Wedbush kept its Outperform rating on Beam Therapeutics and increased its price target to $30 from $28, citing a 13.9% upside from the Nov 3 close. Recent analyst targets for the company range from $28 to $80.

Original reporting
Published Nov 4, 2026, 2:25 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 4, 2026, 2:38 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Wedbush maintains Beam Therapeutics at Outperform, raises price target to $30 from $28 — source image
Decision brief

The 30-second read

$BEAMBullishMed
01

Why it matters

Analyst target upgrades can generate short‑term buying pressure, especially for low‑float biotech stocks.

02

Market read

A fresh analyst upgrade provides a modest trading signal for BEAM, but overall market impact is limited.

03

What to watch

Upcoming clinical trial data or regulatory decisions could dominate price action more than analyst targets.

Relevance 5/10Novelty 5/10Timing: today

Background

Wedbush maintains an Outperform rating on Beam Therapeutics and lifts its price target by 7.1% to $30.

Company-level read

Ticker impact

$BEAMBullishMedium confidence
Context

Wedbush raised its price target on Beam Therapeutics to $30 from $28, indicating a fresh analyst upgrade.

Expected impact

likely modest upward pressure as investors price in the higher target

Evidence & confidence

Analyst upgrades typically prompt short‑term buying, but the change is modest and the stock is small‑cap.

Market effects

Small‑cap biotech may see slight uplift as analysts adjust expectations.

U.S. biotech sector could experience modest positive sentiment.

Limited to investors tracking Beam Therapeutics and similar biotech names.

Counterpoint

The price target increase is modest; the stock may already be fully priced in, limiting upside.

Key entities

  • Beam Therapeutics

    U.S. biotech focused on gene editing.

  • Wedbush

    Equity research firm providing the rating and target.

Related articles

$BEAMHighAI 9/10

Beam Sickle Cell Therapy Meets Pivotal Goals

Beam Therapeutics reported positive pivotal trial results for risto-cel, its sickle cell treatment, meeting all primary and secondary endpoints. The trial showed patients stayed free of severe vaso-occlusive crises for at least 12 months. Beam plans to file for FDA approval by year-end 2026, aiming to be the first base-editing therapy approved in the US. The company will present detailed results at a medical meeting in 2027.